Owing to the function of CR1447 as an AI and AR-modulator, patients with metastatic or locally advanced ER+/HER2− including also ER+/HER2− AR+ breast cancer and triple-negative breast cancers (TNBC) AR+ breast cancer were considered suitable candidates for a phase II trial. This evidence concerns the gene ERBB2 and breast carcinoma.